Immunome/$IMNM
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Immunome
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.
Ticker
$IMNM
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
131
ISIN
US45257U1088
Website
Immunome Metrics
BasicAdvanced
$740M
-
-$3.13
2.01
-
Price and volume
Market cap
$740M
Beta
2.01
52-week high
$16.81
52-week low
$5.15
Average daily volume
1M
Financial strength
Current ratio
10.492
Quick ratio
10.304
Long term debt to equity
1.553
Total debt to equity
1.553
Profitability
EBITDA (TTM)
-175.726
Gross margin (TTM)
-1,280.92%
Net profit margin (TTM)
-1,875.21%
Operating margin (TTM)
-1,625.04%
Revenue per employee (TTM)
$80,000
Management effectiveness
Return on assets (TTM)
-33.54%
Return on equity (TTM)
-69.21%
Valuation
Price to revenue (TTM)
51.043
Price to book
2.41
Price to tangible book (TTM)
2.41
Price to free cash flow (TTM)
-3.121
Free cash flow yield (TTM)
-32.04%
Free cash flow per share (TTM)
-272.64%
Growth
Revenue change (TTM)
-13.76%
Earnings per share change (TTM)
-60.00%
3-year earnings per share growth (CAGR)
4.67%
What the Analysts think about Immunome
Analyst ratings (Buy, Hold, Sell) for Immunome stock.
Bulls say / Bears say
Immunome's acquisition of AL102, a gamma secretase inhibitor currently in Phase III trials for desmoid tumors, positions the company to potentially offer a superior treatment compared to existing therapies, enhancing its oncology portfolio. (nasdaq.com)
The merger with Morphimmune combines complementary technologies, potentially accelerating the development of novel cancer therapies and creating synergistic value for the company. (nasdaq.com)
The successful dosing of the first patient in the Phase 1 trial of IM-1021, a ROR1-targeted antibody-drug conjugate, marks a significant milestone in Immunome's pipeline, indicating progress in its clinical development efforts. (stocktitan.net)
The recent public offering of 19,354,839 shares at $7.75 per share, below the previous closing price, led to a 9.6% decline in stock value, reflecting potential dilution concerns among investors. (investing.com)
Despite strategic acquisitions and mergers, Immunome reported an EBITDA of -$110.44 million in the last twelve months, indicating significant cash burn and raising concerns about financial sustainability. (investing.com)
The stock has experienced a decline of over 52% in the past year, trading near its 52-week low of $8.97, which may reflect investor skepticism about the company's growth prospects. (investing.com)
Data summarised monthly by Lightyear AI. Last updated on 9 Jul 2025.
Immunome Financial Performance
Revenues and expenses
Immunome Earnings Performance
Company profitability
Immunome News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Immunome stock?
Immunome (IMNM) has a market cap of $740M as of July 15, 2025.
What is the P/E ratio for Immunome stock?
The price to earnings (P/E) ratio for Immunome (IMNM) stock is 0 as of July 15, 2025.
Does Immunome stock pay dividends?
No, Immunome (IMNM) stock does not pay dividends to its shareholders as of July 15, 2025.
When is the next Immunome dividend payment date?
Immunome (IMNM) stock does not pay dividends to its shareholders.
What is the beta indicator for Immunome?
Immunome (IMNM) has a beta rating of 2.01. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.